skip to main | skip to sidebar
Just A Life Sciences Blog...

Monday, March 23, 2015

Courtesy of RAPS "Regulatory Focus", The Full Delhi High Court Decision -- On Sitagliptin


My sincere thanks here, go out to the RAPS folks, for sourcing this PDF (~1.8 Mb).

The ruling speaks for itself, and I covered it all, last week. So. . . do enjoy. Onward.

Posted by condor at 5:11 PM
Labels: Aprica Arrives Competition Booms May 1 2013 Januvia Janumet India Patent Glenmark Pharma Sitagliptin Generic February 17 March 1 July 12 2014 March 20 23 2015

No comments:

Post a Comment

Newer Post Older Post Home
Subscribe to: Post Comments (Atom)

Of Banksy's Brilliance...

Of Banksy's Brilliance...
He is sublimely subversive...

The Sacklers, Revisited?

NASA Updates

Tweets by NASA

US Science History...

US Science History...
is immigrants' history...

Of Kenosha 2020...

Of Kenosha 2020...
Hard lessons in how far we still have to go...

Women's March -- Year Two!

Women's March -- Year Two!
Despots are to be resisted...

A Place For S-P Alums




But not affiliated with this site. . . .

Vioxx In the Supreme Court

Vioxx In the Supreme Court
What Was Justice Breyer Asking After?

CEO Hassan's $1.2B Pharmacia Role. . .




. . .in the largest criminal
off-label case in U.S. history.

What Caused The "Bust-Up"?

What Caused The "Bust-Up"?
Mismanaged Disclosure of ENHANCE Results. . . .

Of Direct Marketing Miscues

Of Direct Marketing Miscues
And overwrought protests. . . .

Hassan and Cox, Part Deux?

Hassan and Cox, Part Deux?
From 2000, at Pharmacia. . . .

DOCTOR Stephen Colbert!

DOCTOR Stephen Colbert!
. . . .on Medicine Over-use?

Blog Archive

Senator Grassley's Concern




Was the ENHANCE data actually "blinded"?

stats

The Condor. . . .




What a Great Flick!
Who is he?

Legal Stuff; Creative Commons Statement 2008-2021

Nothing written, appearing, or linked to, on this site is intended to be individual legal, or investment, advice. Consult a financial or legal adviser before making any trade, or any other decision, based anything you read, or see, on this website. This website treats all U.S. viewers' visitor-paths -- and visits -- as public data. If you are from Europe, understand that this site can see -- but will not disclose to the public -- your visitor-path, in compliance with applicable E.U. directives. We also (via enabled cookies) receive useful information about the device and software you use to access these pages, including IP address (from which location may be inferred), device type, web browser type, operating system version, phone carrier and manufacturer, member agents, application installations, device identifiers, mobile advertising identifiers, and push notification tokens. We do not sell any of this information, however -- we are not for profit, here. We automatically receive information about your interactions with these pages, such as the posts or other content you view, the searches you conduct, the people you follow, and the dates and times of your visits. We may collect (for our own use only) information using cookies, pixel tags, and similar technologies. Cookies are small text files containing a string of alphanumeric characters. We may use both session cookies and persistent cookies. A session cookie disappears after you close your browser. A persistent cookie remains after you close your browser and may be used by your browser on subsequent visits to our pages.



All material on this website is derived from public documents, and/or edited, modified, and derived from public domain sources, or in some cases, originally-created by the author(s) of this site. Any use of any proprietary image, document or other data is genuinely-intended by the author(s) to fall under the common-law "fair use" doctrine, as criticism of, and commentary on, matters of substantial public concern -- among them, the for-profit health care system in the Americas. If any person wishes to dispute this assertion of "fair use", please leave a comment in any of the comment-boxes, specifically-identifying the challenged material, and the basis for the challenge, on this site. The Site Administrator(s) will promptly consider the claim. In the same comment-box, the Site Administrator(s) will indicate the site's position on any such claim. This site is not-for-profit. Share, and share-a-like, licenses granted in, and to, all content. Copy-left 2007 through 2023.



blogger.com is great!